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Abstract The high mortality risk of patients with type 2
diabetes mellitus may well be explained by the several
comorbidities and/or complications. Also the intrinsic
genetic component predisposing to diabetes might have a
role in shaping the risk of diabetes-related mortality.
Among type 2 diabetes mellitus SNPs, rs1801282 is of
particular interest because (i) it is harbored by peroxisome
proliferator-activated receptor-c2 (PPARc2), which is the
target for thiazolidinediones which are used as antidiabetic
drugs, decreasing all-cause mortality in type 2 diabetes
mellitus, and (ii) it is associated with insulin resistance and
related traits, risk factors for overall mortality in type 2
diabetes mellitus. We investigated the role of PPARc2
P12A, according to a dominant model (PA ? AA vs. PP
individuals) on incident all-cause mortality in three cohorts
of type 2 diabetes mellitus, comprising a total of 1672
patients (462 deaths) and then performed a meta-analysis
of ours and all available published data. In the three cohorts
pooled and analyzed together, no association between
PPARc2 P12A and all-cause mortality was observed (HR
1.02, 95 % CI 0.79–1.33). Similar results were observed
after adjusting for age, sex, smoking habits, and BMI (HR
1.09, 95 % CI 0.83–1.43). In a meta-analysis of ours and
all studies previously published (n = 3241 individuals; 666
events), no association was observed between PPARc2
P12A and all-cause mortality (HR 1.07, 95 % CI
0.85–1.33). Results from our individual samples as well as
from our meta-analysis suggest that the PPARc2 P12A
does not significantly affect all-cause mortality in patients
with type 2 diabetes mellitus.
Keywords Type 2 diabetes  PPARc2 P12A SNP  Risk
of death  Overall mortality
Introduction
The rate of mortality of patients with type 2 diabetes
mellitus (T2DM) is twice as much as that of non-diabetic
individuals of similar age [1]; this makes diabetes a leading
risk factor for all-cause mortality, accounting for 4.9 mil-
lion deaths worldwide [2]. Such high risk may well be
explained by the several comorbidities and/or chronic
complications which characterize diabetic patients,
including abdominal obesity, hypertension, dyslipidemia,
chronic renal dysfunction, and cardiovascular disease [1,
2]. Beyond these well-established risk factors, it could be
hypothesized that also the intrinsic genetic component
predisposing to diabetes itself has a role in shaping the risk
of diabetes-related mortality. Such an intriguing hypothesis
is compatible with the observation that some single
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nucleotide polymorphisms (SNPs), pointed by genome-
wide association studies (GWAS) as important risk factors
of T2DM, have also been associated with mortality rate,
among diabetic patients [3] as well as non-diabetic indi-
viduals [4].
Among the many so far established T2DM SNPs,
rs1801282 [5] appears to be the most interesting one in
the context of diabetes-related mortality because of sev-
eral reasons: (i) it is harbored by peroxisome proliferator-
activated receptor-c2 (PPARc2) which encodes for a
ligand-activated transcription factor involved in adipose
tissue biology as well as lipid and glucose metabolism [6]
and which, most importantly, is the target for thiazo-
lidinediones, commonly used antidiabetic drugs able to
reduce all-cause mortality in patients with T2DM [7]; (ii)
it is one of the few non-synonymous T2DM SNPs (i.e.,
causing a proline to alanine amino acid substitution at
codon 12; P12A) with a reported biological function as
indicated by in vitro experiments [5]; (iii) it has been
associated with insulin resistance [8], body mass index
[9], high blood pressure [10], myocardial infarction [11,
12], and diabetic nephropathy [13–16], all well-estab-
lished risk factors for overall mortality in patients with
T2DM. Despite this strong background, only two studies
[12, 17] have specifically investigated the role of PPARc2
P12A SNP on all-cause mortality in T2DM, with con-
flicting results.
In order to get deeper insights about this issue, we
investigated the role of PPARc2 P12A on incident all-cause
mortality in three cohorts of T2DM, comprising a total of
1672 Italian patients from a very homogeneous geograph-
ical area (i.e., Northern Apulia, in Central-Southern Italy),
whose demographic and clinical features are carefully
characterized [18, 19]. Subsequently, a meta-analysis on
ours plus all available published data was carried out.
Materials and methods
Ethics statement
The study and the informed consent procedures were
approved by the local Institutional Ethic Committee
IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico)
‘‘Casa Sollievo della Sofferenza’’ and performed accord-
ing to the Helsinki Declaration. All participants gave
written consent.
Patients
We studied three previously described [18, 19] cohorts of
patients with T2DM (according to ADA 2003 criteria),
followed up for all-cause mortality.
The Gargano Mortality Study (GMS)
One thousand twenty-eight Whites from Italy with T2DM
were consecutively recruited at Scientific Institute ‘‘Casa
Sollievo della Sofferenza’’ in San Giovanni Rotondo
(Apulia, Central-Southern Italy) for a study aimed at
unraveling predictors of incident all-cause mortality. The
only exclusion criterion was the presence of poor life
expectancy due to malignancies. Up to date, this cohort has
been followed up for 10.7 ± 3.6 years (range: 0.1–14.1),
with the last information on vital status being obtained on
November 30, 2014. After excluding patients (i) whose
information on vital status at follow-up was not available
(n = 9), (ii) who had missing information on PPARc2
P12A genotype at baseline (n = 103), and (iii) who were
also part of the Gargano Heart Study (n = 116) (see
below), 800 patients (77.8 % of the initial cohort) consti-
tuted the eligible sample for the present investigation.
The Gargano Heart Study (GHS)
Three hundred forty Whites from Italy with T2DM and
coronary heart disease, as indicated by previous myocardial
infarction or 50 % stenosis of at least one major vessel at
coronary angiography, or both, were consecutively recrui-
ted at Scientific Institute ‘‘Casa Sollievo della Sofferenza’’
in San Giovanni Rotondo from 2000 to 2008. The only
exclusion criterion was the presence of poor life expec-
tancy due to malignancies. Up to date, this cohort has been
followed up for 5.5 ± 2.5 years (range: 0.1–9.9), with the
last information on vital status being obtained on March
31, 2011. After excluding patients (i) whose information on
vital status at follow-up was not available (n = 23) and (ii)
who had missing information on PPARc2 P12A genotype
at baseline (n = 39), 278 patients (81.8 % of the initial
cohort) constituted the eligible sample for the present
investigation.
The Foggia Mortality Study (FMS)
One thousand one hundred two Whites from Italy with
T2DM were consecutively recruited at Endocrine Unit of
University of Foggia (Apulia, Central-Southern Italy) from
January 7, 2002 to September 30, 2008, for a study aimed
at unraveling predictors of incident all-cause mortality.
Also in this case, the only exclusion criterion was the
presence of poor life expectancy due to malignancies. Up
to date, this cohort has been followed up for
7.1 ± 1.4 years (range: 4.4–11.7), with the last information
on vital status being obtained on March 31, 2014. After
excluding patients (i) whose information on vital status at
follow-up was not available (n = 101) and (ii) from whom
DNA was not obtained (n = 407), 594 patients (53.9 % of
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the initial cohort) constituted the eligible sample for the
present analysis.
Data collection
At baseline, all patients were interviewed regarding age at
diabetes diagnosis, smoking habits, and ongoing anti-dia-
betes, anti-dyslipidemia, and anti-hypertension treatments.
Duration of diabetes was calculated from the calendar year
of data collection minus the calendar year of diabetes
diagnosis. All subjects enrolled in the study underwent
physical examination, including measurements of height,
weight, body mass index (BMI; Kg/m2), and blood pres-
sure (two measurements rounded to the nearest 2 mmHg in
the sitting position after at least 5 min rest, using an
appropriate-sized cuff; diastolic blood pressure was recor-
ded at the disappearance of Korotokoff sound, phase V).
Fasting venous blood was sampled from an antecubital
vein from all patients for the measurement of total serum
cholesterol (enzymatic method, Cobas; Roche Diagnostics,
Welwin Garden City, U.K.), HDL-cholesterol, serum
triglycerides (enzymatic method, Cobas), and HbA1c
(HPLC Diamat Analyzer; Bio-Rad, Richmond, CA); LDL-
cholesterol was then calculated by the Friedewald formula.
Genotyping
Genomic DNA was extracted from peripheral blood
according to standard procedures. The PPARc2 P12A SNP
(rs1801282) was genotyped by a TaqMan Pre-Designed
SNP genotyping assay (C_1129864_10, Applied Biosys-
tems, Foster City, CA) on ABI 7900HT genetic analyzer.
Genotyping quality was tested by including six blinded
duplicate samples in each 96-well assay. The average
agreement rate of duplicate samples was greater than 99 %.
Study endpoint
All-cause mortality was the only predetermined end point
of this study. At follow-up, the vital status of study patients
was ascertained by two authors for each study, either by
telephone interview with the patient or his/her relatives or
by queries to the registry office of cities of residence. For
GMS, the last follow-up was carried out by queries to the
Italian Health Card (http://sistemats1.sanita.finanze.it/wps/
portal/portalets/cittadinots/ts).
Search strategy and selection criteria
In order to perform a meta-analysis comprising data from
our three study samples and those from published studies,
two investigators (AP and SDC) independently searched
PubMed and Web of Science for prospective studies with
PPARc2 P12A as exposure and all-cause mortality as
outcome, published until July 2015. Search terms used
were (PPARc2 Pro12Ala or PPARc2 P12A or PPARc SNP
or peroxisome proliferator-activated receptor gamma 2
Pro12Ala or peroxisome proliferator-activated receptor
gamma 2 P12A or peroxisome proliferator-activated
receptor gamma 2 SNP or rs1801282) and (mortality or
death rate). Exclusion criteria were i) non-original papers;
ii) study population other than type 2 diabetes; iii) different
outcomes. The quality of the eligible studies was assessed
by availability of data on both clinical features and distri-
bution of allele/genotype and by available information on
HWE and genetic model utilized, as well. SDC and AP
extracted the data from such studies. No disagreements
were observed.
Statistical analysis
Patients’ baseline characteristics were reported as
mean ± standard deviation (SD) and frequency (percent-
age) for continuous and categorical variables, respectively.
The exact test for Hardy–Weinberg equilibrium (HWE)
was carried out as previously described [20].
Overall age- and sex-adjusted mortality rates were
assessed using Poisson model and expressed as number of
deaths per 100 person-years. The overall survival was
defined as the time between enrollment and death; for
subjects who did not experience the end point, survival
time was censored at the time of the last available follow-
up visit. Time-to-death analyses were performed using
univariable and multivariable Cox proportional hazards
regression models and risks were reported as hazard ratios
(HR) along with their 95 % confidence intervals (CI). To
test the effect of P12A genotype on all-cause mortality, due
to the very low frequency of AA genotypes, HRs were
reported for the presence of PA ? AA (named as XA) vs.
PP genotypes, according to a dominant model of
inheritance.
Pooled data meta-analysis was performed using a linear
mixed-effect modeling and according to a dominant model
of inheritance because only the latter genetic model was
reported in the previous published studies selected for our
meta-analysis.
Statistical heterogeneity among studies was assessed
using the Cochran Q-test and heterogeneity hold for p val-
ues less than 0.10 [21]. Study-specific estimates were
pooled using either the fixed-effects model or, in presence
of heterogeneity (i.e., Q-test statistically significant), the
random effects model [22]. Following Sterne et al. [23] and
Ioannidis et al. [24] recommendations, the publication bias
was evaluated by the visual inspection of a funnel plot
(with a 95 % pseudo-CI region) without performing any
statistical test, due to the small number of studies (fewer
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than ten). For forest plot, a square was plotted for each
study whose center projection on the underlying scale
corresponds to the study-specific HR. The area of the
square was proportional to the inverse of the variance of
the logarithm transformation of HR (i.e., precision of the
HR estimates) and thus gives a measure of the amount of
statistical information available from that particular esti-
mate. A diamond was used to plot the summary HRs, the
center of which represents the HR; the extremes of the
summary HRs show the 95 % CI.
A p value\0.05 was considered to be statistically sig-
nificant. All analyses were performed using SAS Release
9.3 (SAS Institute, Cary, NC, USA) and R 2.15 (package:
metafor).
Sample size calculation
A sample of 1672 subjects (GMS, GHS, and FMS)
achieves 80 % (or 90 %) power, assuming a Type I Error
of 5 %, to detect an HR of 1.39 (or 1.45) assuming a
dominant model of inheritance (see above) and an antici-
pated event rate of 0.28, the average value of our three
samples (see below).
Results
Present studies
Baseline clinical features of the 1672 T2DM patients from
the three study samples are reported in Table 1. Minor
allele (i.e. A12) frequency was similar in the three samples
(Table 1). Clinical features were not different across P12A
genotypes in any study sample (data not shown).
In GMS (follow-up = 10.7 years), GHS (follow-
up = 5.5 years), and FMS (follow-up = 7.1 years), 246
(30.7 %), 64 (23.0 %), and 152 (25.6 %) patients died,
with an age- and sex-adjusted annual mortality rate of 2.2,
3.8, and 2.5 per 100 person-years, respectively.
Genotype distribution did not depart from the HWE in
GMS and FMS (p values: 0.419 and 0.351, respectively)
and minimally did so in GHS (p = 0.023).
Given the very low number of patients homozygous for
the A allele, data from such individuals were pooled
together with those from PA patients, considered as a
single group and named as XA individuals.
Mortality incidence rates in each cohort across geno-
type groups are reported in Table 2, while Table 3 shows
the HRs (95 %CI) for all-cause mortality, following a
dominant genetic model of the P12A genotypes.
Given the absence of heterogeneity in the association
with all-cause mortality (i.e. p for study sample-by-SNP
interaction = 0.56), the three cohorts were pooled and
analyzed together, so to increase statistical power. In a
model where only ‘‘study sample’’ was used as adjusting
covariate, no significant association between PPARc2
P12A and all-cause mortality was observed (Table 3).
Similar results were observed when also age, sex, smoking
habits, and BMI were added into the model.
In post hoc analyses on pooled data, no effect on the
association between the P12A SNP and all-cause mortality
was observed after stratifying individuals according to
either BMI status (\30 kg/m2, n = 803; C30 kg/m2,
n = 810; BMI data were missing for 59 individuals; p for
SNP-by-BMI status interaction = 0.25) or sex (male,
n = 862; female, n = 810; p for SNP-by-sex
interaction = 0.46).
In addition, in the GHS, where data on death of car-
diovascular origin were also available, no association
between PPARc2 P12A and cardiovascular mortality was
observed (p = 0.48, following a dominant genetic model
of inheritance).
Meta-analysis on present and previous studies
Eighteen papers passed the filter of our inclusion criteria.
Of those, 15 papers were excluded because they were
(i) reviews rather than original papers (n = 2); (ii) inves-
tigating individuals from sets other than T2DM, including
either the general population (n = 6), or type 1 diabetes
mellitus (n = 1), or coronary artery disease (n = 2), or end
stage renal disease (n = 1), or lung cancer disease (n = 1);
(iii) with different study designs either for the exposure
variable (i.e., variability of the PPARa, rather than
PPARc2, gene, n = 1) or the outcome of interest (i.e., renal
dysfunction, rather than all-cause mortality, n = 1). At the
end of this process, two studies [12, 17] were considered
eligible for our meta-analysis (Fig. 1). In the Go-DARTS,
2016 Whites with T2DM were enrolled; mean age and
duration of diabetes were 64.4 and 7.9 years, respectively.
No other clinical information is available about this sam-
ple. In the Szeto’s study, all 220 subjects had T2DM and
diabetic nephropathy with GFR\60 ml/min; mean age and
duration of diabetes were 65.2 and 6.6 years in pre-dialysis
patients, 60.9 and 7.9 years in dialysis patients; mean BMI
was 22.0 kg/m2 in pre-dialysis patients and 22.4 kg/m2 in
dialysis patients; systolic and diastolic blood pressure were
144.7 and 80.9, 151.0, and 82.1 mmHg in pre-dialysis and
dialysis patients, respectively. Genotyping for PPARc2
Pro12Ala was performed using Taqman (Applied Biosys-
tem) allelic discrimination assays in the Go-DARTS and
PCR–RFLP analysis in Szeto’s study; both samples were in
HWE. In both studies included in the meta-analysis, the
multivariable model (Cox hazards model) comprised age,
sex, cholesterol, and blood pressure; in addition, Doney’s
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study also included in the model duration of diabetes,
triglycerides, and BMI; Szeto’s study also included HbA1c,
GFR, proteinuria, CRP, and Charlson’s comorbidity score.
We then performed an aggregate data meta-analysis
comprising data from our three study samples and those
from Doney et al. [12] and from Szeto et al. [17] (Q-test
p for heterogeneity = 0.19), for a total of 3241 individuals
and 666 events. As clearly shown in Fig. 2, no significant
association was observed between PPARc2 P12A SNP
(XA vs. PP genotypes) and all-cause mortality (HR 1.07,
95 % CI 0.85–1.33, p = 0.57). Moreover, no publication
bias was detected by the visual inspection of the funnel plot
(Fig. 3).
Discussion
The established role of T2DM in increasing mortality risk
[1, 2] makes reasonable testing the association between
genetic determinants of T2DM and all-cause mortality rate
[3, 4]. In the specific context of the PPARc2 P12A SNP,
which has been reported to shape the risk not only of
T2DM but also of insulin resistance [8], body mass index
[9], high blood pressure [10], myocardial infarction [11,
12], and diabetic nephropathy [13–16], it is conceivable to
hypothesize a reduced mortality risk among T2DM sub-
jects carrying the A allele. However, the data we here
present on a total of 3241 individuals clearly indicates a
neutral effect of the PPARc2 P12A SNP on all-cause
mortality in T2DM.
In addition, neither BMI nor gender, which have been
reported to influence the association between the P12A
SNP and T2DM [25], cardiovascular events [26], human
longevity [27, 28], and adiposity [29], played a role as
modifiers of the P12A SNP effect on mortality rate.
No association between this SNP and all-cause mortality
was observed not only in each of our three study samples,
but also in patients from the large Go-DARTS [12], making
thus not surprising that no association at all was observed
in the meta-analysis of all so far available studies, com-
prising a total of 3241 individuals and 666 events. In all,
although the small Szeto’s study reported a significant
Table 1 Baseline clinical
features of study patients with
type 2 diabetes mellitus
GMS n = 800 GHS n = 278 FMS n = 594
Sex (M/F) 389/411 183/95 290/304
Age (years) 61.6 ± 9.8 64.6 ± 8.0 63.1 ± 11.9
Body mass index (kg/m2) 30.1 ± 5.8 30.4 ± 5.0 30.1 ± 6.2
Smokers: n (%) 109 (13.6) 48 (18.6) 90 (16.5)
Duration of diabetes (years) 10.4 ± 8.7 14.5 ± 9.5 13.3 ± 10
Glycated hemoglobin (%) 8.7 ± 2.0 8.7 ± 1.9 8.9 ± 2.2
Systolic blood pressure (mmHg) 135.1 ± 16.4 135.2 ± 20.0 130.6 ± 15.2
Diastolic blood pressure (mmHg) 78.8 ± 8.8 76.2 ± 10.0 76.5 ± 9.0
Low density lipoprotein cholesterol (mg/dl) 121.3 ± 38.0 102.9 ± 39.5 100.8 ± 37.1
Antidiabetic therapy
Diet alone: n (%) 110 (14.2) 17 (6.4) 73 (13)
Oral antidiabetic drugs: n (%) 344 (44.6) 90 (34.1) 272 (48.5)
Insulin ± oral antidiabetic drugs: n (%) 318 (41.2) 157 (59.5) 213 (38.5)
Anti-hypertensive therapy: n (%) 389 (53.2) 235 (85.8) 395 (70.3)
Anti-dyslipidemic therapy: n (%) 233 (29.3) 173 (64.3) 211 (37.6)
Number of patients with PP/PA/AA genotype 691/107/2 238/35/5 509/84/1
MAF (%) 6.9 8.1 7.2
Data are expressed as mean ± standard deviation (SD) or frequency (percentage)
GMS Gargano Mortality Study, GHS Gargano Heart Study, FMS Foggia Mortality Study, PP patients
homozygous for the P variant, PA heterozygous patients, AA patients homozygous for the A variant. MAF
minor allele frequency (A12 in our case)
Table 2 Mortality incidence rates, along with 95 % confidence
intervals, in PPARc2 PP and XA (i.e., PA/AA) genotypes
PP XA
GMS 2.9 (95 % CI 2.5–3.3) 2.8 (95 % CI 2.0–4.0)
GHS 4.3 (95 % CI 3.3–5.6) 3.4 (95 % CI 1.7–6.7)
FMS 3.5 (95 % CI 2.9–4.1) 4.3 (95 % CI 3.0–6.3)
Incidence rates are expressed as number of death events per 100
person-years, along with their 95 % confidence interval (95 % CI)
GMS Gargano Mortality Study, GHS Gargano Heart Study, FMS
Foggia Mortality Study, PP patients homozygous for the P variant,
XA heterozygous patients or patients homozygous for the A variant
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association, a minimal and definitively not significant
heterogeneity across all results was observed, thus mini-
mizing the risk that the lack of some information from the
two previous studies has flawed our meta-analysis. Our
negative data are in contrast with those of two GWAS-
derived genetic variations associated with T2DM, includ-
ing that at 9p21 chromosome (i.e., rs10811661, near
CDKN2A/CDKN2B) and that at the TCF7L2 locus (i.e.,
rs7903146) for which, in fact, an association with all-cause
mortality was reported either in diabetic [3] or in non-
diabetic [4] individuals. Such reported associations are
somehow surprising, given that the two latter SNPs do not
play any role on insulin resistance; rather, they affect
insulin secretion [30], which is not known to affect mor-
tality risk. So, present and previous [3, 4] data on the role
of GWAS-derived SNPs for T2DM on mortality rate sug-
gest that those of them which modulate the risk of death
rather than doing so through their deleterious effect on
Table 3 Hazard ratios, along with 95 % confidence intervals, of all-cause mortality for PPARc2 PA/AA versus PP genotypes
Model adjustments HR 95 % CI p value
GMS Unadjusted 0.97 0.67–1.41 0.87
Adjusted for age, sex, smoking habits, and body mass index 1.16 0.80–1.69 0.44
GHS Unadjusted 0.79 0.38–1.66 0.54
Adjusted for age, sex, smoking habits, and body mass index 1.10 0.49–2.48 0.82
FMS Unadjusted 1.01 0.67–1.55 0.95
Adjusted for age, sex, smoking habits, and body mass index 0.80 0.51–1.27 0.34
Whole sample Adjusted for study sample 1.02 0.79–1.33 0.86
Adjusted for study sample, age, sex, smoking habits, and body mass index 1.09 0.83–1.43 0.53
GMS Gargano Mortality Study; GHS Gargano Heart Study, FMS Foggia Mortality Study
Results are reported as Hazard Ratios (HR), along with their 95 % confidence interval (95 % CI). Outcome: all-cause mortality
Search terms: (PPARγ2 Pro12Ala or PPARγ2 P12A or PPARγ SNP
or peroxisome proliferator-activated receptor gamma 2 Pro12Ala
or peroxisome proliferator-activated receptor gamma 2 P12A
or peroxisome proliferator-activated receptor gamma 2 SNP
or rs1801282) and (mortality or death rate)
Studies excluded because investigating variability at PPARα, 
rather than PPARγ2, as the exposure variable (n=2),
and the risk of diabetic nephropathy,
rather than that of all-cause mortality, as the outcome (n=1)
2 articles included in the meta-analysis
Studies excluded because being reviews 
rather than original papers (n=2) 
Studies excluded because investigating individuals 
either from the general population (n=6),  
or with type 1 diabetes (n=1), or coronary artery disease (n=2), 
or end stage renal disease (n=1), or lung cancer disease (n=1).
18 articles
Fig. 1 Search strategy for selecting studies to include in meta-analysis for the association between PPARc2 P12A SNP and all-cause mortality
risk (search last run on July 2015)
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glucose homeostasis are likely to act through a yet unrav-
eled, pleiotropic effect on different pathways.
We recently reported a combined effect of insulin signaling
genes, which contribute to both insulin resistance [31] and
T2DM [32] on all-cause mortality [33], a finding which is fully
compatible with the well-known deleterious role of insulin
resistance on risk of mortality rate [34, 35]. Previous [33] and
present data, taken together, are compatible with the hypoth-
esis that not all forms of insulin resistance are deleterious for
life expectancy with only those based on altered insulin sig-
naling, but not those presumably based on abnormal adipose
tissue biology, being really able to increase the risk of death.
Fig. 2 Forest plot for fixed-effects meta-analysis for the association
between PPARc2 P12A SNP (following a dominant model of
inheritance) and all-cause mortality risk. GMS Gargano Mortality
Study, GHS Gargano Heart Study, FMS Foggia Mortality Study.
Results are reported as Hazard Ratios (HR), along with their 95 %
confidence intervals (95 % CI). Model adjustments: GMS, GHS, and
FMS: data are adjusted for age, sex, smoking habits, and body mass
index. Doney et al.: data are provided as adjusted for age, sex, and
smoking habits. Szeto et al.: data are provided as unadjusted
Fig. 3 Funnel plot for fixed-
effects meta-analysis for the
association between PPARc2
P12A (following a dominant
model of inheritance) and all-
cause mortality. GMS Gargano
Mortality Study, GHS Gargano
Heart Study, FMS Foggia
Mortality Study. HR Hazard
Ratios. Vertical reference line
was drawn to intercept the
X-axis at the pooled HR
estimate
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The strength of our study is that the three samples here
analyzed are quite homogenous in terms of clinical features
and both environmental and genetic backgrounds, the two
Institutions in which recruitment was carried out being
only 50 kilometers apart. As a matter of fact, these samples
have been very useful in our hands in addressing the role
on mortality rate in T2DM of several genetic [33, 36] and
non-genetic risk factors [37–42].
It is worth to underline that, given the geographical
homogeneity of the population studied, the effect of pop-
ulation stratification was not explored and that, following
Sterne et al. [23] and Ioannidis et al. [24] recommenda-
tions, we did not perform tests for publication bias, due to
the small number of studies meta-analyzed. Also because
of this, no study-specific results were assessed.
Our data have to be taken with caution, keeping in mind
that we cannot exclude that in T2DM the P12A SNP is
associated with less than 40 % increased risk of mortality
rate, a cut-off below which we do not have enough statis-
tical power to draw firm conclusions. We call for caution
also because while the three largest studies so far carried
out in different clinical sets have obtained similar negative
data [12, 43, 44], some smaller studies have reported
positive, though conflicting, data, including increasing [45]
or decreasing [46] all-cause mortality rate in homozygous
individuals for the A12 variant or increasing of such rate
[47] in homozygous individuals for the P12 variant.
Finally, in two of our three study cohorts we had no
information on cardiovascular mortality, thus making it
impossible to robustly investigate the role of P12A SNP on
it, which has been previously described in normoglycemic
males with symptomatic coronary artery disease at baseline
and on 40 mg/day pravastatin treatment [48].
In conclusion, results from our individual samples as
well as from our meta-analysis of all available studies
suggest that the PPARc2 P12A SNP does not significantly
affect all-cause mortality in patients with T2DM.
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